Prelude Capital Management’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-1,265
| Closed | -$56.4K | – | 1277 |
|
|
2024
Q1 | $56.4K | Buy |
1,265
+390
| +45% | +$17.4K | ﹤0.01% | 1135 |
|
|
2023
Q4 | $34K | Buy |
+875
| New | +$34K | ﹤0.01% | 954 |
|
|
2023
Q3 | – | Sell |
-638
| Closed | -$40.6K | – | 1127 |
|
|
2023
Q2 | $40.6K | Sell |
638
-912
| -59% | -$58K | ﹤0.01% | 867 |
|
|
2023
Q1 | $73.2K | Buy |
+1,550
| New | +$73.2K | ﹤0.01% | 882 |
|